plus
therapeutics
receives
fast
track
designation
fda
novel
glioblastoma
treatment
austin
texas
globe
newswire
plus
therapeutics
nasdaq
pstv
company
today
announced
food
drug
administration
fda
granted
company
fast
track
designation
lead
investigational
drug
rhenium
nanoliposomes
rnl
treatment
patients
recurrent
glioblastoma
previously
reported
company
also
received
orphan
drug
designation
fda
rnl
treatment
patients
glioblastoma
fast
track
designation
confers
several
benefits
drug
development
program
including
frequent
meetings
fda
discuss
drug
development
plan
frequent
written
communication
fda
things
design
proposed
clinical
trials
use
biomarkers
eligibility
accelerated
approval
priority
review
relevant
criteria
met
rolling
review
means
drug
company
submit
completed
sections
new
drug
application
nda
review
fda
rather
waiting
every
section
nda
completed
entire
application
reviewed
nda
review
usually
begin
drug
company
submitted
entire
application
fda
fast
track
designation
validates
potential
importance
novel
radiotherapeutic
patients
recurrent
glioblastoma
currently
good
treatment
options
said
marc
hedrick
president
chief
executive
officer
plus
therapeutics
designation
hand
intend
move
cohort
trial
one
key
step
closer
bringing
forth
novel
therapy
rnl
evaluated
nih
phase
clinical
trial
reported
last
week
respect
trials
data
safety
monitoring
board
dsmb
approved
company
proceed
cohort
trial
includes
increasing
drug
volume
radiation
dose
milliliters
ml
millicuries
mci
respectively
rnl
designed
safely
effectively
conveniently
deliver
high
dose
radiation
times
greater
concentration
currently
used
external
beam
radiation
therapy
directly
brain
tumor
maximum
effect
glioblastoma
glioblastoma
grade
iv
astrocytoma
common
aggressive
primary
malignant
brain
tumors
adults
according
recent
central
brain
tumor
registry
united
states
cbtrus
statistical
report
average
nearly
cases
glioblastoma
diagnosed
annually
historical
median
survival
rates
respectively
plus
therapeutics
plus
therapeutics
nasdaq
pstv
pharmaceutical
company
whose
radiotherapeutic
portfolio
concentrated
radionuclides
several
cancer
targets
central
company
drug
development
unique
nanotechnology
platform
designed
reformulate
deliver
commercialize
multiple
drugs
targeting
rare
cancers
diseases
platform
designed
facilitate
new
delivery
approaches
formulations
safe
effective
injectable
drugs
potentially
enhancing
safety
efficacy
convenience
patients
healthcare
providers
information
may
found
cautionary
statement
regarding
statements
press
release
contains
certain
statements
may
deemed
statements
within
meaning
securities
laws
statements
statements
historical
fact
address
activities
events
developments
intend
expect
project
believe
anticipate
similar
expressions
future
conditional
verbs
would
could
may
occur
future
statements
statements
based
upon
certain
assumptions
assessments
made
management
light
experience
perception
historical
trends
current
conditions
expected
future
developments
factors
believe
appropriate
statements
include
without
limitation
statements
company
potential
facilitate
new
delivery
approaches
formulations
safe
effective
injectable
drugs
potentially
enhancing
safety
efficacy
convenience
patients
healthcare
providers
company
potential
develop
drug
candidates
currently
product
pipeline
company
potential
develop
additional
drugs
outside
current
pipeline
statements
included
press
release
subject
number
additional
material
risks
uncertainties
including
limited
risk
company
able
successfully
develop
product
candidates
leverage
fda
accelerated
regulatory
pathways
risks
described
heading
risk
factors
company
securities
exchange
commission
filings
including
company
annual
quarterly
reports
may
events
future
company
unable
predict
control
business
financial
condition
results
operations
prospects
may
change
future
company
assumes
responsibility
update
revise
statements
reflect
events
trends
circumstances
date
made
unless
company
obligation
federal
securities
laws
investor
contact
peter
vozzo
westwicke
icr
media
contact
terri
clevenger
westwicke
icr
